4/A: Revolution Medicines Director Corrects Stock Option Award in Amended SEC Filing

Frank Clyburn, a director at Revolution Medicines, files an amendment to a previous Form 4 to correct the amount of a stock option award granted on August 5, 2024.

Summary

• Frank Clyburn, a director of Revolution Medicines, filed an amended Form 4 with the SEC to correct a previously reported stock option award.
• The original Form 4, filed on August 7, 2024, inadvertently reported an incorrect amount for the stock option award granted on August 5, 2024.
• The corrected filing shows that Clyburn was granted a stock option to purchase 26,540 shares of Revolution Medicines common stock at an exercise price of $42.48.
• The option vests monthly over three years, starting August 5, 2024, contingent upon Clyburn's continued service with the company.
• The options expire on August 5, 2034.

Sentiment

Score: 7

Explanation: The document is a routine correction of a previously filed form, indicating standard corporate governance procedures. The sentiment is neutral to slightly positive as it reflects transparency and adherence to regulatory requirements.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The correction of the stock option award ensures accurate information is available to shareholders.

Key Dates

Keywords

Form 4, Amendment, Stock Option, Revolution Medicines, RVMD, Frank Clyburn, Director, SEC Filing